23 Juni 2020

BioVersys Receives QIDP Designation from the U.S. FDA for the Development of a fixed combination of BVL-GSK098 and ETH

Basel, Switzerland. June, 23rd, 2020. 09:00 CEST BioVersys develops BVL-GSK098, in collaboration with GSK, as an entirely new mechanism to poten...


05 Mai 2020

GARDP signs MOU with Swiss biotech BioVersys AG

The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Swiss biopharmaceutical company BioVersys to...


04 Nov. 2019

BioVersys Receives CARB-X Award of up to US$ 8.92 Million

CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, o...


20 Juni 2019

BioVersys announces a EUR 6.92 Million funding of its TRIC-TB project by the IMI2 JU and extends its successful collaboration with long term partners

BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreemen...